CN100368029C - 用磁性复合微粒对血液中病毒及细胞清除的方法及装置 - Google Patents
用磁性复合微粒对血液中病毒及细胞清除的方法及装置 Download PDFInfo
- Publication number
- CN100368029C CN100368029C CNB2004100262212A CN200410026221A CN100368029C CN 100368029 C CN100368029 C CN 100368029C CN B2004100262212 A CNB2004100262212 A CN B2004100262212A CN 200410026221 A CN200410026221 A CN 200410026221A CN 100368029 C CN100368029 C CN 100368029C
- Authority
- CN
- China
- Prior art keywords
- blood
- magnetic composite
- composite particle
- virus
- magnetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 91
- 239000008280 blood Substances 0.000 title claims abstract description 90
- 241000700605 Viruses Species 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 45
- 239000002131 composite material Substances 0.000 title abstract 2
- 239000008187 granular material Substances 0.000 title description 2
- 239000011246 composite particle Substances 0.000 claims abstract description 72
- 239000010836 blood and blood product Substances 0.000 claims abstract description 14
- 229940125691 blood product Drugs 0.000 claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 13
- 239000007790 solid phase Substances 0.000 claims abstract description 3
- 239000003463 adsorbent Substances 0.000 claims description 23
- 230000017531 blood circulation Effects 0.000 claims description 10
- 239000004531 microgranule Substances 0.000 claims description 6
- 230000008676 import Effects 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 238000009827 uniform distribution Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 abstract description 8
- 239000002245 particle Substances 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000036285 pathological change Effects 0.000 abstract description 4
- 238000000926 separation method Methods 0.000 abstract description 4
- 231100000915 pathological change Toxicity 0.000 abstract description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 28
- 239000006249 magnetic particle Substances 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 230000009849 deactivation Effects 0.000 description 10
- 241000711549 Hepacivirus C Species 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 208000036142 Viral infection Diseases 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000009385 viral infection Effects 0.000 description 7
- 210000002845 virion Anatomy 0.000 description 7
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 239000004005 microsphere Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 2
- 238000007445 Chromatographic isolation Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- -1 amino, carboxyl Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000005672 electromagnetic field Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- ZBKIUFWVEIBQRT-UHFFFAOYSA-N gold(1+) Chemical compound [Au+] ZBKIUFWVEIBQRT-UHFFFAOYSA-N 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 208000014951 hematologic disease Diseases 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 108090000145 Bacillolysin Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000035092 Neutral proteases Human genes 0.000 description 1
- 108091005507 Neutral proteases Proteins 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000001856 aerosol method Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000498 ball milling Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- CWAFVXWRGIEBPL-UHFFFAOYSA-N ethoxysilane Chemical compound CCO[SiH3] CWAFVXWRGIEBPL-UHFFFAOYSA-N 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 239000002120 nanofilm Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 238000003980 solgel method Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100262212A CN100368029C (zh) | 2004-06-08 | 2004-06-08 | 用磁性复合微粒对血液中病毒及细胞清除的方法及装置 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100262212A CN100368029C (zh) | 2004-06-08 | 2004-06-08 | 用磁性复合微粒对血液中病毒及细胞清除的方法及装置 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1583185A CN1583185A (zh) | 2005-02-23 |
CN100368029C true CN100368029C (zh) | 2008-02-13 |
Family
ID=34601258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100262212A Expired - Lifetime CN100368029C (zh) | 2004-06-08 | 2004-06-08 | 用磁性复合微粒对血液中病毒及细胞清除的方法及装置 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100368029C (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101273996B (zh) * | 2007-03-30 | 2012-11-07 | 陕西北美基因股份有限公司 | 净化血液及血液制品的方法 |
CN102258818A (zh) * | 2011-04-13 | 2011-11-30 | 俞能旺 | 体外循环癌细胞净化系统 |
US10737276B2 (en) * | 2015-01-27 | 2020-08-11 | Circulomics Inc. | Hierarchical silica lamella for magnetic nucleic acid extraction |
CN107049594B (zh) | 2017-06-14 | 2020-04-07 | 京东方科技集团股份有限公司 | 回收装置以及磁性微粒回收方法 |
CN110227195B (zh) * | 2019-05-05 | 2021-09-28 | 朗姿赛尔生物科技(广州)有限公司 | 一种血液中病毒及病变细胞的清除方法 |
CN115177803A (zh) * | 2022-06-02 | 2022-10-14 | 厦门大学附属翔安医院 | 一种新冠病毒感染患者血液中病毒的清除方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5123901A (en) * | 1988-02-25 | 1992-06-23 | Carew E Bayne | Method for separating pathogenic or toxic agents from a body fluid and return to body |
CN1221630A (zh) * | 1997-12-31 | 1999-07-07 | 沈阳机电研究设计院 | 核磁共振净化器 |
US5980479A (en) * | 1997-07-02 | 1999-11-09 | Idializa Ltd. | Method and system for correcting a biological fluid |
WO2002026292A1 (de) * | 2000-09-28 | 2002-04-04 | Affina Immuntechnik Gmbh | Durchflussvorrichtung zum trennen von substanzen in körperflüssigkeiten, insbesondere blut und dessen verwendung |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
-
2004
- 2004-06-08 CN CNB2004100262212A patent/CN100368029C/zh not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5123901A (en) * | 1988-02-25 | 1992-06-23 | Carew E Bayne | Method for separating pathogenic or toxic agents from a body fluid and return to body |
US5980479A (en) * | 1997-07-02 | 1999-11-09 | Idializa Ltd. | Method and system for correcting a biological fluid |
CN1221630A (zh) * | 1997-12-31 | 1999-07-07 | 沈阳机电研究设计院 | 核磁共振净化器 |
JP2002165591A (ja) * | 2000-09-25 | 2002-06-11 | Jsr Corp | 磁性粒子およびその使用方法 |
WO2002026292A1 (de) * | 2000-09-28 | 2002-04-04 | Affina Immuntechnik Gmbh | Durchflussvorrichtung zum trennen von substanzen in körperflüssigkeiten, insbesondere blut und dessen verwendung |
Also Published As
Publication number | Publication date |
---|---|
CN1583185A (zh) | 2005-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100408160C (zh) | 纳米大小的正电性非纺织滤器 | |
JP5079506B2 (ja) | 動物についての、バイオテクノロジー(生物学的研究を含む)および医学的診断での適用のための、細胞、生体粒子および/または分子を液体から単離するための装置ならびに方法 | |
Williams et al. | Affinity capture of a biotinylated retrovirus on macroporous monolithic adsorbents: Towards a rapid single‐step purification process | |
JP2009000536A (ja) | 細胞外体液からの特異的生体高分子物質の体外捕獲 | |
WO2012142180A1 (en) | Methods to detect and treat diseases | |
WO2010081076A2 (en) | Imprinted polymer nanoparticles | |
JPS61235752A (ja) | 細胞分離材、分離器および分離方法 | |
CN100368029C (zh) | 用磁性复合微粒对血液中病毒及细胞清除的方法及装置 | |
CN102838674A (zh) | 一种利用蛋白a的高密度包被磁珠纯化抗体的方法 | |
US6730230B2 (en) | Use of high density microparticles for removal of pathogens | |
Öztürk et al. | Silane‐modified magnetic beads: application to immunoglobulin G separation | |
US20100069815A1 (en) | Substrate for biological fluid treatment | |
CN101273996B (zh) | 净化血液及血液制品的方法 | |
Kohno et al. | Inhibition of interferon production by chloroquine diphosphate | |
AU654381B2 (en) | Process for producing magnetically responsive polymer particles and application thereof | |
Heldt et al. | Identification of trimeric peptides that bind porcine parvovirus from mixtures containing human blood plasma | |
JP2024506857A (ja) | 磁性粒子と使い捨て製品接触材料を使用することにより混合物から生体材料を精製するための自動化デバイスおよび方法 | |
JP2007238479A (ja) | ハイドロキシアパタイトに吸着された有機物の溶出方法及び該溶出方法を用いた有機物の精製方法 | |
CN102319439B (zh) | 一种带磁性微球的药物及用途 | |
JPH0114791B2 (zh) | ||
CN109627334A (zh) | 一种纳米抗体、以该纳米抗体为配基的吸附剂及其用途 | |
Matheka et al. | Activated sepharose as an adsorbent for antibodies of foot-and-mouth disease virus, and its use as an immunoadsorbent for type and subtype differentiation | |
JPH0316639A (ja) | 吸着体およびそれを用いた除去装置 | |
JPS63252252A (ja) | Bリンパ球分離材、分離方法および分離器 | |
RU2120308C1 (ru) | Колонка для сорбции биологических жидкостей |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: XI'AN GOLDMAG NANOBIOTECH Co.,Ltd. Assignor: Shaanxi North American Gene Co.,Ltd. Contract record no.: 2011610000162 Denomination of invention: Method and apparatus for removing virus and cells from blood by magnetic composite micro-granules Granted publication date: 20080213 License type: Exclusive License Open date: 20050223 Record date: 20110901 |
|
ASS | Succession or assignment of patent right |
Owner name: XI AN GOLDMAG NANOBIOTECH CO., LTD. Free format text: FORMER OWNER: SHAANXI BAIMEI GENE CO., LTD. Effective date: 20130906 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: SHAANXI BAIMEI GENE CO., LTD. Free format text: FORMER NAME: SHAANXI LIFEGEN CO., LTD. Owner name: SHAANXI LIFEGEN CO., LTD. Free format text: FORMER NAME: XIDA BEIMEI GENE CO., LTD., SHANXI |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 710002 XI AN, SHAANXI PROVINCE TO: 710077 XI AN, SHAANXI PROVINCE |
|
CP01 | Change in the name or title of a patent holder |
Address after: 710002 Shaanxi city of Xi'an Province South Gate Albert building A--9L Patentee after: SHAANXI LIFEGEN Co.,Ltd. Address before: 710002 Shaanxi city of Xi'an Province South Gate Albert building A--9L Patentee before: Shaanxi North American Gene Co.,Ltd. Address after: 710002 Shaanxi city of Xi'an Province South Gate Albert building A--9L Patentee after: Shaanxi North American Gene Co.,Ltd. Address before: 710002 Shaanxi city of Xi'an Province South Gate Albert building A--9L Patentee before: Shanxi Lifegen Co.,Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130906 Address after: 710077, Shaanxi, Xi'an hi tech Zone, No. 85, No. 4, No. 2, modern enterprise center, 3 east side, 10402A Patentee after: XI'AN GOLDMAG NANOBIOTECH Co.,Ltd. Address before: 710002 Shaanxi city of Xi'an Province South Gate Albert building A--9L Patentee before: SHAANXI LIFEGEN Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20080213 |